Biotech: Page 24


  • burnout concept
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Conditions for worker burnout in biotech are ripe. Here’s how to beat it

    One of the country’s leading burnout experts explains how companies can help keep high stress from becoming a high desire to leave the job.

    By April 19, 2023
  • Elle de Groot Brii Bioscience
    Image attribution tooltip
    Permission granted by Elle de Groot
    Image attribution tooltip
    Podcast

    Woman of the Week: Brii Biosciences’ Ellee de Groot

    A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.

    By April 19, 2023
  • Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Chris Benecchi, chief business officer, Sage Therapeutics
    Image attribution tooltip
    Permission granted by Sage
    Image attribution tooltip
    Q&A

    Depression has long been treated chronically — Sage wants to change that

    Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

    By April 18, 2023
  • eyes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Profile

    A CMO’s quest to tackle infectious diseases leads him to an eye condition that’s often overlooked

    How an “international” childhood sent Dr. José Trevejo, Tarsus’s chief medical officer, on a mission to fight infectious diseases.

    By Alexandra Pecci • April 18, 2023
  • COVID vaccine development
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A new era of COVID innovation is here

    With a $5 billion dollar infusion, a new White House program is helping catalyze development of next-gen treatments, from pan-coronavirus vaccines to enhanced antivirals. 

    By Kelly Bilodeau • April 17, 2023
  • Awan Ahsan
    Image attribution tooltip
    Permission granted by Ahsan Awan
    Image attribution tooltip
    Q&A

    5 minutes with — Genlantis Diagnostics’ Ahsan Awan

    A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”

    By April 14, 2023
  • Dave Hering
    Image attribution tooltip
    Permission granted by Invivyd Therapeutics
    Image attribution tooltip
    Profile

    He helped launch the Pfizer COVID vaccine — now this startup CEO is hunting a lingering pandemic foe

    All of the COVID-19 mAbs have been pulled from the market. But Dave Hering, CEO of Invivyd, hopes to change that.

    By April 11, 2023
  • blood sample tubes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Where one unicorn struggled, another biotech is aiming for a diabetes win

    Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

    By Kelly Bilodeau • April 10, 2023
  • RSV vaccine panel, World Vaccine Congress.
    Image attribution tooltip
    Michael Gibney/PharmaVoice
    Image attribution tooltip

    Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

    Although Janssen bowed out of the RSV vaccine race, several pharmas are quickly closing in on the finish line in a disease with decades of unmet need.

    By April 6, 2023
  • A scientist with protective eyeglasses and mask holding a red transparent pill with fingers in gloves in the pharmaceutical research laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A drug just launched for a disease discovered only 10 years ago

    Pharming just landed an FDA approval for a treatment targeting an ultra-rare immunodeficiency disorder discovered only a decade ago — and it’s already in the hands of patients.

    By Karissa Waddick • April 6, 2023
  • Theresa Heah Intergalactic Therapeutics
    Image attribution tooltip
    Permission granted by Theresa Heah
    Image attribution tooltip
    Podcast

    Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

    Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm...

    By April 5, 2023
  • Silver lining
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The silver linings in biotech’s wobbly market

    A report from accounting firm BDO compares biotech’s tough times with the booming last few years — and points to some silver linings.

    By April 4, 2023
  • Chantel Moderna
    Image attribution tooltip
    Permission granted by Moderna
    Image attribution tooltip
    Profile

    Moderna exec: ‘There is nothing but global health’

    How Chantal Friebertshäuser is helping lead Moderna’s plan to expand its global reach.  

    By Alexandra Pecci • April 4, 2023
  • A science lab with no workers
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Staff shortages cause slowdowns in booming cell and gene therapy market

    New reports highlight the need for more targeted biotech education curriculums to shore up a sustainable workforce.

    By Karissa Waddick • April 3, 2023
  • dollar bill brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

    In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

    By Kelly Bilodeau • April 3, 2023
  • magic wand
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Opinion

    Leaders wave a magic wand at pharma’s thorniest issues

    The major challenges pharma leaders would solve with a quick flick of an imaginary wand.

    By PharmaVoice staff • March 31, 2023
  • Rich Christie, chief medical officer, AiCure
    Image attribution tooltip
    Permission granted by AiCure
    Image attribution tooltip
    Q&A

    Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

    Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

    By March 30, 2023
  • A whiteboard with a stick-figure smiling phage sits on a desk in biotech laboratory
    Image attribution tooltip
    Karissa Waddick/PharmaVoice
    Image attribution tooltip

    Predator and prey: Harnessing phages to fight antibiotic resistance

    Phages, bacteria’s natural predator, could help combat the growing threat of superbugs. But can these therapies rise above antibiotic market woes?

    By Karissa Waddick • March 30, 2023
  • pill explosion
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Seamless clinical trials were created to make studies easier — instead, they’ve become more complex

    Experts weigh in on how companies can design better trials that merge two phases into one.

    By March 29, 2023
  • Jackie von Salm Psilera
    Image attribution tooltip
    Permission granted by Jackie von Salm
    Image attribution tooltip
    Podcast

    Woman of the Week: Psilera’s Jackie von Salm

    Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm.

    By March 29, 2023
  • U.S. Supreme Court building
    Image attribution tooltip
    Al Drago/Getty Images via Getty Images
    Image attribution tooltip

    SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

    The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market.

    By March 28, 2023
  • Head on chalkboard with light bulb notes inside
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    How one of the world’s sharpest inventors keeps the ideas coming. Hint: It’s not at work

    Steve Quake, head of science for the Chan Zuckerberg Initiative, who’s had several “once-in-a-lifetime” ideas, provides advice on how to find inspiration.

    By Alexandra Pecci • March 27, 2023
  • A TV remote points up at a blurred-out screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cutting the cord — why streaming is a new frontier for pharma advertising

    As streaming services proliferate, and more TV watchers buy in, there’s a new world of possibilities for DTC pharma marketing.

    By Karissa Waddick • March 27, 2023
  • Multi-colored panels against black background and brand logo
    Image attribution tooltip
    Permission granted by ProtaGene
    Image attribution tooltip
    Sponsored by ProtaGene

    Biosimilars Market Poised for an Exciting Future

    As the biologics industry approaches its next patent cliff, what is the state of the biosimilars market?

    March 27, 2023
  • magic wand
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Opinion

    What would you fix with a ‘magic wand?’ Pharma leaders chime in about clinical trials

    How life science execs would transform clinical trials with a little hocus pocus.

    By PharmaVoice staff • March 24, 2023